// App-Quantinova.ai

AB0846 (2018) : Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost effective strategy in spondyloarthritis

Researchers

Presenter

  • S. Dubash

Principal Investigators

  • D. Bryer

  • J. Fitton

  • A. Barr

  • C. Vandevelde

  • H. Marzo-Ortega

  • J. Freeston

Medical Centers

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved